• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Major Progress Achieved on R&D Landscape for Sleeping Sickness, One of the Most Neglected Diseases

19 May 2009

Today, there is important progress to report at all stages of DNDi’s drug R&D pipeline for sleeping sickness, with projects moving forward to address the treatment needs of some of the most neglected patients.

Commonly known as sleeping sickness, human African trypanosomiasis (HAT) is a fatal illness which threatens 60 million people in 36 countries, primarily in sub-Saharan Africa.

The two current treatment options for stage 2 HAT are inadequate:
• Melarsoprol is toxic (associated with 3-6% fatality) and increasingly ineffective
• Eflornithine: inconvenient to use (56 slow intravenous infusions administered every 6 hours over 14 days) and only used in approximately 30% of stage 2 HAT patients for that reason
NECT, a simplified co-administration of oral nifurtimox and intravenous eflornithine, can make an immediate, practical improvement for patients and health care staff today. If NECT is effectively implemented as a replacement for melarsoprol, it could save 4 to 5 lives for every 100 patients treated as there is much less toxicity with NECT. This is critical as there are no new drugs for stage 2 HAT expected in the next five years. Although NECT radically improves upon current treatment options by being safer to use than melarsoprol and far easier to use than eflornithine, the treatment is still far from ideal.
Having a truly simplified treatment which can be orally administered, implemented at the primary health care level, and effective against both stages of the disease, is still the ultimate goal. Drugs for Neglected Diseases initiative is pleased to announce that fexinidazole is entering clinical development for HAT and that we have signed an agreement with sanofi-aventis for its further development. Additionally, the pipeline is being strengthened by renewed commitments of the United Kingdom’s Department for International Development and research partners like Anacor towards the discovery of new drugs against HAT.


NOW AVAILABLE FOR USE: AN IMMEDIATE IMPROVEMENT FOR PATIENTS WITH STAGE 2 HAT

• NECT, the nifurtimox-eflornithine combination therapy: the first improved treatment in 25 years is now included on the WHO’s Essential Medicines List and is now available for use in treating stage 2 HAT
• May 15: MSF, Epicentre and DNDi announce that NECT is on WHO Essential Medicines List
• NECT is an improved option because it’s much easier to use and as efficacious / safe as eflornithine
• Clinical evidence from a 5-year, multicentre, randomized controlled trial in central Africa, represents some of the strongest evidence in the field to date
• According to WHO, NECT “provides a new opportunity to improve the management of sleeping sickness cases” by reducing treatment duration and making it easier to administer…
• Key donors for NECT-related DNDi activities: the Department for International Development (DFID) of the United Kingdom, Médecins Sans Frontières (MSF) International, the Medicor Foundation, the Ministry of Foreign and European Affairs (MAEE) of France, and the Spanish Agency of International Cooperation for Development (AECID).


COLLABORATION TO DEVELOP A PROMISING NEW DRUG CANDIDATE

• FEXINIDAZOLE: has potential to be an oral treatment effective against both stages of sleeping sickness; a collaboration agreement with sanofi-aventis announced yesterday
• “Rediscovered” by DNDi after extensive compound mining efforts with industry and academia
• Entering clinical development in 2009 and the only new clinical candidate currently in the drug pipeline for sleeping sickness
• Offers the potential of an oral treatment that can treat both stages of disease (no painful lumbar punctures and no more infusions over 2 weeks)
• May 18: Sanofi-aventis and DNDi sign agreement to develop and make available a new drug for sleeping sickness, fexinidazole
• The following donors have financially supported DNDi’s fexinidazole-related activities: DFID of the United Kingdom, GTZ of Germany, MSF, MAEE of France, the Spanish AECID, and a Swiss foundation.

DNDI’S PARTNERS STRENGTHEN COMMITMENTS
• Private biopharma: This week, the biopharmaceutical company, Anacor, and DNDi will announce their continuing partnership on boron-based therapeutics for sleeping sickness and others neglected diseases
• Public donor: The UK’s Department for International Development (DFID) renews multi-year support of DNDi’s efforts to improve medicines for the most neglected, with a 5-year, GBP 18 million grant

Partnership Sleeping sickness

Read, watch, share

Loading...
Healthcare worker attending a training
Press releases
10 Jul 2025

New HIV project in the DRC brings life-saving care closer to people with advanced HIV disease

Woman working in a laboratory
News
10 Jul 2025

LEO Foundation partners with DNDi to develop breakthrough drug discovery model for mycetoma 

Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

Press releases
13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

News
10 Jun 2025

Bringing life-saving care closer to people living with HIV in Kinshasa 

News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License